newsfilter
← Earnings
Earnings Releases·

Foghorn Therapeutics — Third Quarter 2026 Earnings Summary

  • Collaboration revenue surged to $83.5 million from $8.2 million year-over-year, driven by a $74.1 million cumulative catch-up adjustment, resulting in a net income of $58.2 million versus a $15.8 million loss in the prior year.
  • R&D expenses decreased to $18.8 million and G&A expenses fell to $5.8 million, while the company recorded $2.3 million in restructuring costs following the decision not to advance FHD-909 and the SMARCA2 selective degrader programs.
  • Cash and marketable securities stood at $156.2 million as of September 30, 2026, with management projecting a cash runway extending into the second half of 2029.
  • Future outlook includes dose-range finding studies for the IBD program in Q4 2026, with first-in-human trials targeted for end-2027 and an IND filing for the EP300 degrader program expected in 2027.
Company
FOGHORN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology